Study Details

Back to Search Results

Phase 2 study of Maintenance OSI-906 plus Erlotinib (Tarceva®), or Placebo plus Erlotinib in patients with nonprogression following 4 cycles of platinum-based chemotherapy

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT01186861

Astellas Study ID

The unique identification code given by the study sponsor.

OSI-906-205

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

2010-020916-12

Follow Trial

Condition

Non Small Cell Lung Cancer

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

18 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Mar 2011 - Mar 2015

Masking

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Enrollment number

205

A Randomized, Double-Blind, Placebo-controlled Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Erlotinib Plus Placebo in Patients With Nonprogression Following Four Cycles of 1st-line Platinum-based Chemotherapy for Advanced NSCLC

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for Phase 2 study of Maintenance OSI-906 plus Erlotinib (Tarceva®), or Placebo plus Erlotinib in patients with nonprogression following 4 cycles of platinum-based chemotherapy? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site RO40006

Craiova, Romania, 200535

Site RU70011

Saint Petersburg, Russian Federation, 197089

Site DE49005

Minden, Germany, 32429

Site BR55016

Goiania, Brazil, 74605-030

Site CA11001

Oshawa, Canada, L1G 2B9

Site BR55015

Cachoeiro de Itapemirim, Brazil, 29308-014

Site RU70001

Moscow, Russian Federation, 129128

Site KR82002

Seoul, Republic of Korea, 137-701

Site PL48005

Szczecin, Poland, 70-891

Site US10006

Buffalo, United States, 14215

Site US10004

Greensboro, United States, 27403

Site BR55005

Barretos, Brazil, 14784-400

Site GB44005

London, United Kingdom, NW1 2PQ

Site CA11003

Montreal, Canada, H2W 1S6

Site CA11004

Ottawa, Canada, K1H 8L6

Site US10011

Scarborough, United States, 04074

Site BR55006

Ijui, Brazil, 98700-000

Site BR55003

Fortaleza, Brazil, 60336-550

Site DE49015

Kassel, Germany, 34125

Site KR82003

Seoul, Republic of Korea, 120-752

Site PL48002

Elblag, Poland, 82-300

Site GB44001

Manchester, United Kingdom, M20 4BX

Site DE49009

Homburg/Saar, Germany, 66421

Site PL48008

Torun, Poland, 87-100

Site CA11008

Montreal, Canada, H2W 1S6

Site US10002

Albany, United States, 31701

Site BR55013

Porto Alegre, Brazil, 90430-090

Site US10001

Port St. Lucie, United States, 34952

Site RO40001

Baia Mare, Romania, 490110

Site RO40005

Alba Iulia, Romania, 510077

Site BR55011

Florianopolis, Brazil, 88034-000

Site GB44003

Leeds, United Kingdom, LS9 7TF

Site RU70004

Saint Petersburg, Russian Federation, 197758

Site DE49008

Koln, Germany, 51109

Site BR55001

Itajai, Brazil, 88301-220

Site DE49013

Mainz, Germany, 55131

Site DE49002

Hemer, Germany, 58675

Site DE49001

Heidelberg, Germany, 69126

Site KR82008

Incheon, Republic of Korea, 400-711

Site CA11006

Toronto, Canada, M5G 1X5

Site RO40003

Cluj-Napoca, Romania, 400015

Site KR82004

Seongnam-si, Republic of Korea, 463-707

Site RO40004

Hunedoara, Romania, 331057

Site CA11002

Toronto, Canada, M6R 1B5

Site PL48004

Warsaw, Poland, 02-781

Site KR82005

Seoul, Republic of Korea, 135-710

Site KR82001

Suwon, Republic of Korea

Site BR55012

Ribeirao Preto, Brazil, 14515-130

Site BR55004

Brasilia, Brazil, 70840-050

Site RU70009

Saint Petersburg, Russian Federation, 197089

Site GB44002

Leicester, United Kingdom, LE1 5WW

Site PL48003

Warszawa, Poland, 01-138

Site BR55009

Londrina, Brazil, 86050-190

Site DE49014

Berlin, Germany, 10117

Site DE49012

Karlsruhe, Germany, 76137

Site BR55014

Porto Alegre, Brazil, 90610-000

Site GB44006

Dundee, United Kingdom, DD1 9SY

Site KR82007

Busan, Republic of Korea, 602-715

Site RU70007

Saint Petersburg, Russian Federation, 194291

Site DE49003

Grosshansdorf, Germany, 22977

Site RO40007

Brasov, Romania, 500366

Site GB44007

Bristol, United Kingdom, BS2 8ED

Site DE49011

Dortmund, Germany, 44145

Site RO40002

Cluj-Napoca, Romania, 400015

Site DE49006

Immenhausen, Germany, 34376

Site US10010

Winston-Salem, United States, 27103

Site KR82006

Hwasun, Republic of Korea, 519-809

Site GB44004

Southampton, United Kingdom, SO16 6YD

Site RU70010

Kazan, Russian Federation, 420029

Site BR55002

Rio de Janeiro, Brazil, 20231-050

Site US10007

Jacksonville, United States, 32207

Site RU70002

Chelaybinsk, Russian Federation, 454087

Site PL48006

Wroclaw, Poland, 53-439

Site BR55008

Piracicaba, Brazil, 13419-155

Site US10005

Morristown, United States, 07962-1089

Site BR55007

Sao Paulo, Brazil, 01323-920

Site US10008

Chicago, United States, 60612

Site CA11007

Montreal, Canada, H2W 1S6

Site RU70008

Nizhniy Novgorod, Russian Federation, 603081

Site DE49010

Lubeck, Germany, 23538

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo